Latigo Biotherapeutics Adds Experienced CFO to Board and Audit Committee

According to a recent LinkedIn post from Latigo Biotherapeutics, the company is highlighting the appointment of Sara Bonstein to its Board of Directors and as Chair of the Audit Committee. The post notes that Bonstein currently serves as CFO of Insmed and brings more than two decades of financial and operational leadership in the biotech sector.

The post suggests that her experience in capital strategy, corporate governance, and scaling organizations is expected to support Latigo’s efforts to advance its pipeline and develop a leading non‑opioid pain franchise. For investors, this board-level addition may indicate a focus on strengthening financial oversight and preparing for future financing or strategic transactions as the company enters what it describes as its next phase of growth.

The emphasis on non‑opioid pain management aligns Latigo with ongoing industry and regulatory interest in alternatives to traditional opioid therapies. If Bonstein’s governance and capital markets background contributes to smoother execution of clinical and corporate milestones, the move could enhance Latigo’s positioning among emerging pain-focused biotechs and potentially improve its access to capital over time.